Previously, a variety of genes signatures associated with tumor immune microenvironment and immunotherapy response for pediatric or adult AML patients were established (29–33), and studies have reported on potential clinical benefits of immunotherapy against AML, including targeting CD33, CD123, and several immune checkpoint inhibitors (ICIs) (4, 34). Here, CD33 is linked to acute myeloid leukemia.